FSD Pharma Inc
CNSX:HUGE
Relative Value
There is not enough data to reliably calculate the relative value of HUGE.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
HUGE Competitors Multiples
FSD Pharma Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
F
|
FSD Pharma Inc
CNSX:HUGE
|
14.3m CAD | 0 | -1 | -0.8 | -0.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.9B USD | 15.1 | 47.8 | 32.2 | 34.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD | 6.3 | 22.3 | 15.4 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
293B CHF | 4.6 | 30.3 | 12.8 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.7B CHF | 5.7 | 22.8 | 14.1 | 18.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.5B GBP | 5.4 | 31.2 | 17.2 | 24.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.9B USD | 4.7 | 16.8 | 10.4 | 12.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.3 | 10.1 | 7.5 | 8.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD | 2.5 | 20.2 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 7.4 | 9.2 |